MedTrace Logo

A Study of SGB-9768 in Adult Healthy Volunteers

NCT06501573 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-01-22

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768 in healthy volunteers. The purpose is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768.

Conditions

  • Healthy Volunteer

Interventions

DRUG

SGB-9768

SGB-9768 for sc injection

OTHER

Placebo

sterile normal saline (0.9% NaCl) for sc injection

Sponsors & Collaborators

  • Suzhou Sanegene Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-06
Primary Completion
2025-05-03
Completion
2025-10-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06501573 on ClinicalTrials.gov